» Authors » Patrick J Lillie

Patrick J Lillie

Explore the profile of Patrick J Lillie including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 31
Citations 5005
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Drozd M, Hamilton F, Cheng C, Lillie P, Brown O, Chaddock N, et al.
J Infect . 2024 Sep; 89(5):106262. PMID: 39241967
Background: Infectious diseases are a major cause of mortality in spite of existing public health, anti-microbial and vaccine interventions. We aimed to define plasma proteomic associates of infection mortality and...
2.
Lee I, Cosgrove C, Moore P, Bethune C, Nally R, Bula M, et al.
Lancet Infect Dis . 2023 Jun; 23(9):1007-1019. PMID: 37348519
Background: The omicron BA.1 bivalent booster is used globally. Previous open-label studies of the omicron BA.1 (Moderna mRNA-1273.214) booster showed superior neutralising antibody responses against omicron BA.1 and other variants...
3.
Shaw R, Greenland M, Stuart A, Aley P, Andrews N, Cameron J, et al.
J Infect . 2023 Apr; 86(6):574-583. PMID: 37028454
Background: Heterologous COVID vaccine priming schedules are immunogenic and effective. This report aims to understand the persistence of immune response to the viral vectored, mRNA and protein-based COVID-19 vaccine platforms...
4.
Mortimer I, Drury K, Lowe S, Akhtar M, Barlow G, Easom N, et al.
J Infect . 2022 Jun; 85(4):436-480. PMID: 35724756
No abstract available.
5.
Drozd M, Pujades-Rodriguez M, Morgan A, Lillie P, Witte K, Kearney M, et al.
J Infect Dis . 2022 May; 226(3):554-562. PMID: 35535512
Background: Many diseases are associated with chronic inflammation, resulting in widening application of anti-inflammatory therapies. Although they are effective as disease-modifying agents, these anti-inflammatory therapies increase the risk of serious...
6.
Stuart A, Shaw R, Liu X, Greenland M, Aley P, Andrews N, et al.
Lancet . 2021 Dec; 399(10319):36-49. PMID: 34883053
Background: Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19...
7.
Drozd M, Pujades-Rodriguez M, Sun F, Franks K, Lillie P, Witte K, et al.
J Am Heart Assoc . 2021 Nov; 10(22):e023188. PMID: 34743561
Background Therapeutic advances have reduced cardiovascular death rates in people with cardiovascular diseases (CVD). We aimed to define the rates of cardiovascular and noncardiovascular death in people with specified CVDs...
8.
Lillie P, OBrien P, Lawtie M, Jessop S, Easom N, Patmore R
Clin Infect Dis . 2021 Apr; 73(10):1906-1908. PMID: 33893480
Over the first 2 months of 2021, vaccination coverage of staff at Hull Teaching Hospitals with BNT162b2 increased from 8.3% to 82.5% and was associated with a significant reduction in...
9.
Emary K, Golubchik T, Aley P, Ariani C, Angus B, Bibi S, et al.
Lancet . 2021 Apr; 397(10282):1351-1362. PMID: 33798499
Background: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of...
10.
Drozd M, Pujades-Rodriguez M, Lillie P, Straw S, Morgan A, Kearney M, et al.
Lancet Infect Dis . 2021 Mar; 21(8):1184-1191. PMID: 33662324
Background: Non-communicable diseases (NCDs) have been highlighted as important risk factors for COVID-19 mortality. However, insufficient data exist on the wider context of infectious diseases in people with NCDs. We...